Chong Kun Dang's 2025 Earnings Decline and 54% Dividend Cut Amid Governance Improvements: Shareholder Value Recovery Key


  • Consolidated revenue increased 6.7% to KRW 1.69 trillion in 2025, but operating profit plunged 19% to KRW 80.5 billion and net income dropped 30% to KRW 77.8 billion, driven by higher R&D and SG&A costs.
  • Dividend per share was cut 54% to KRW 500 (yield 0.6%) from KRW 1,100 in 2024, with no formal dividend policy, heightening uncertainty for income-focused investors.
  • Issued KRW 61.1 billion zero-coupon exchangeable bonds (conversion price KRW 97,500, a 23% premium to current price) for facility investment; dilution risk is limited but proceeds must be tracked.
  • Governance improvements include a CEO succession policy, appointment of a female inside director, and robust internal controls (ISO 37001, 37301), though shortcomings remain: AGM notice only 14 days prior, no dividend policy, and no audit committee.
  • Contingent liabilities of KRW 110.3 billion in guarantees and KRW 68.3 billion in loans to joint venture PT CKD OTTO expose the company to currency and credit risks.
  • [AI Summary]Chong Kun Dang's 2025 earnings slump and dividend cut have eroded short-term shareholder value, but governance enhancements and growth investments via exchangeable bonds offer medium-term upside. The lack of a clear dividend policy and contingent liabilities warrant continued vigilance.

KOSPI Filing Information


  • Filing: Corporate Governance Report Disclosure
  • Company: Chong Kun Dang Pharmaceutical (185750)
  • Submission: Chong Kun Dang Pharmaceutical Corp.
  • Receipt: 06-01-2026
  • Under KRX KOSPI Market Division